Hematologic profiles with bortezomib in relapsed MM

被引：0
|
作者：
Lonial, S.
Richardson, P. G.
Miguel, J. San
Sonneveld, P.
Schuster, M.
Blade, J.
Cavenagh, J.
Rajkumar, V.
Jakubowiak, A.
Esseltine, D.
Anderson, K. C.
Harousseau, J.
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Hosp Univ Salamanca, Salamanca, Spain
[4] Univ Rotterdam Hosp, Rotterdam, Netherlands
[5] NY Presbyterian Hosp, New York, NY USA
[6] Univ Barcelona, Barcelona, Spain
[7] St Bartholomews Hosp, London, England
[8] Mayo Clin, Rochester, MN USA
[9] Univ Michigan, Ann Arbor, MI 48109 USA
[10] Millennium Pharmaceut Inc, Cambridge, MA USA
[11] Hop Hotel Dieu, Nantes, France
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
MULTIPLE-MYELOMA; REFRACTORY MYELOMA; PHASE-2;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：159 / 160
页数：2
相关论文
共 50 条
  • [41] Bortezomib in Relapsed or Refractory Waldenstrom's Macroglobulinemia
    Chen, Christine
    Kouroukis, C. Tom
    White, Darrell
    Voralia, Michael
    Stadtmauer, Edward
    Stewart, A. Keith
    Wright, John J.
    Powers, Jean
    Walsh, Wendy
    Eisenhauer, Elizabeth
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (01): : 74 - 76
  • [42] Carfilozomib versus bortezomib for relapsed or refractory myeloma
    Vogl, Steven E.
    LANCET ONCOLOGY, 2016, 17 (04): : E125 - E126
  • [43] Bortezomib survival projection in relapsed multiple myeloma
    Reece, D.
    Grima, D.
    Attard, C.
    Jivraj, F.
    Yoong, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 158 - 159
  • [44] Panobinostat plus bortezomib and dexamethasone for relapsed myeloma
    Pratt, Guy
    Lancet Haematology, 2016, 3 (11): : E498 - E499
  • [45] Bortezomib and gemcitabine in relapsed Hodgkin lymphoma (HL)
    Friedberg, Jonathan W.
    Kelly, Jennifer
    Voci, Susan
    Marquis, Diana
    Rich, Lynn
    Rossi, Randall
    Bernstein, Steven
    Jordan, Craig
    Liesveld, Jane
    Fisher, Richard I.
    BLOOD, 2007, 110 (11) : 688A - 688A
  • [46] Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
    Tommaso Caravita
    Paolo de Fabritiis
    Antonio Palumbo
    Sergio Amadori
    Mario Boccadoro
    Nature Clinical Practice Oncology, 2006, 3 : 374 - 387
  • [47] Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies
    Jackson, G
    Einsele, H
    Moreau, P
    San Miguel, J
    CANCER TREATMENT REVIEWS, 2005, 31 (08) : 591 - 602
  • [48] Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
    Caravita, Tommaso
    de Fabritiis, Paolo
    Palumbo, Antonio
    Amadori, Sergio
    Boccadoro, Mario
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (07): : 374 - 387
  • [49] Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
    Pawel Robak
    Tadeusz Robak
    Drugs in R&D, 2019, 19 : 73 - 92
  • [50] Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
    Robak, Pawel
    Robak, Tadeusz
    DRUGS IN R&D, 2019, 19 (02) : 73 - 92
12345